Total synthesis of topopyrones B and D

Organic Letters

Volumn 8, Issue 21, 2006, Pages 4771-4774

  Tan, Jason Samuel ^a   Ciufolini, Marco A ^a  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ANTHRAQUINONE DERIVATIVE; DNA TOPOISOMERASE; PYRONE DERIVATIVE; TOPOPYRONE B; TOPOPYRONE D;

ARTICLE; CHEMICAL STRUCTURE; CHEMISTRY; DRUG ANTAGONISM; STRUCTURE ACTIVITY RELATION; SYNTHESIS;

ANTHRAQUINONES; DNA TOPOISOMERASES, TYPE I; MOLECULAR STRUCTURE; PYRONES; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 33750315712     PISSN: 15237060     EISSN: None     Source Type: Journal    
DOI: 10.1021/ol0617291     Document Type: Article

References (27)

1. Recent review: Champoux, J. J. Annu. Rev. Biochem. 2001, 70, 369.
2. Denny, W. A. Expert Opin. Emerging Drugs 2004, 9, 105.
3. (b) Advances in Pharmacology; Liu, L. F., Ed.; Academic Press: San Diego, CA, 1994; Vol. 29B.
4. Recent review: Kellner, U.; Sehested, M.; Jensen, P. B.; Gieseler, F.; Rudolph, P. Lancet Oncol. 2002, 3, 235.
5. Reviews: (a) Rothenberg, M. L. Ann. Oncol. 1997, 8, 837.
6. (b) Versace, R. W. Expert Opin. Ther. Pat. 2003, 13, 1.
7. Isolation: (a) Edwards, R. L.; Fawcett, V.; Maitland, D. J.; Nettleton, R.; Shields, L.; Whalley, A. J. S. J. Chem. Soc., Chem. Commun. 1991, 1009.
8. Bioactivity: (b) Gimbert, Y.; Chevenier, E.; Greene, A. E.; Massardier, C.; Piettre, A. EP 01 402 551 4, 2001.
9. Synthetic work: (c) Piettre, A.; Chevenier, E.; Massardier, C.; Gimbert, Y.; Greene, A. E. Org. Lett. 2002, 4, 3139.
10. (d) Chevenier, E.; Lucatelli, C.; Pandya, U.; Wang, W.; Gimbert, Y.; Greene, A. E. Synlett 2004, 2693.
11. Review: Dias, N.; Vezin, H.; Lansiaux, H.; Lansiaux, A.; Bailly, C. Top. Curr. Chem. 2005, 253, 89.
12. (a) Kanai, Y.; Ishiyama, D.; Senda, H.; Iwatani, W.; Takahaski, H.; Konno, H.; Tokumasu, S.; Kanazawa, S. J. Antibiot. 2000, 53, 863.
13. (b) Ishiyama, D.; Kanai, Y.; Senda, H.; Iwatani, W.; Takahashi, H.; Konno, H.; Kanazawa, S. J. Antibiot. 2000, 53, 873.
14. 50 = 0.15 ng/mL for 3 vs 0.10 ng/mL for camptothecin.
15. Qi, L. Dissertation; Brown University: Providence, RI, 2003: Diss. Abstr. Int., B 2003, 64, 1737.
16. (a) Wang, X.; Snieckus, V. Synlett 1990, 313.
17. See also: (b) De Silva, S. O.; Watanabe, M.; Snieckus, V. J. Org. Chem. 1979, 44, 4802.
18. The preparation of this material is described in the Supporting Information.
19. Langer, P.; Freifeld, I. Synlett 2001, 4, 523.
20. Calculations were performed with the Hyperchem package, available from Hypercube, Inc.
21. The computed value is a lower limit for the rotational energy barrier (which is notoriously difficult to calculate with precision) because there is no actual eclipsing between the aryl carbons and the alkyl or OTIPS residues.
22. These yields are somewhat disappointing. However, the one-pot process of Scheme 2 permits a high degree of convergency, and it involves three distinct, sequential reactions (nucleophilic addition of the lithiated benzamide to 8, halogen-metal exchange, and intramolecular addition of the aryllithium derivative of 16 to the amide carbonyl). An overall yield of 20% thus corresponds to an average 58% yield per step.
23. Snieckus, V. Chem. Rev. 1990, 90, 879.
24. Whisler, M. C.; MacNeil, S.; Snieckus, V.; Beak, P. Angew. Chem., Int. Ed. 2004, 43, 2206.
25. Sibi, M. P.; Jalil Miah, M. A.; Snieckus, V. J. Org. Chem. 1984, 49, 737.
26. More, J. D.; Finney, N. S. Org. Lett. 2002, 4, 3001.
27. See Supporting Information for pertinent data.